Your browser is no longer supported. Please, upgrade your browser.
Entasis Therapeutics Holdings Inc.
Index- P/E- EPS (ttm)-3.36 Insider Own52.60% Shs Outstand29.96M Perf Week31.91%
Market Cap105.46M Forward P/E- EPS next Y-1.23 Insider Trans35.34% Shs Float13.57M Perf Month29.71%
Income-53.80M PEG- EPS next Q-0.39 Inst Own31.00% Short Float0.60% Perf Quarter44.86%
Sales0.00M P/S- EPS this Y-3.50% Inst Trans- Short Ratio0.11 Perf Half Y-4.62%
Book/sh2.08 P/B1.49 EPS next Y49.00% ROA-101.50% Target Price- Perf Year-36.85%
Cash/sh- P/C- EPS next 5Y- ROE-118.70% 52W Range1.58 - 5.64 Perf YTD25.51%
Dividend- P/FCF- EPS past 5Y- ROI-112.80% 52W High-45.04% Beta-
Dividend %- Quick Ratio10.00 Sales past 5Y- Gross Margin- 52W Low96.20% ATR0.23
Employees47 Current Ratio10.00 Sales Q/Q- Oper. Margin- RSI (14)71.49 Volatility9.64% 9.12%
OptionableNo Debt/Eq0.00 EPS Q/Q-40.00% Profit Margin- Rel Volume0.52 Prev Close3.01
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume736.49K Price3.10
Recom1.90 SMA2020.62% SMA5044.82% SMA20022.91% Volume391,179 Change2.99%
Sep-09-20Initiated Cantor Fitzgerald Overweight $5
Jul-13-20Initiated ROTH Capital Buy $9
Jan-07-21 08:00AM  
Dec-01-20 01:52AM  
Nov-17-20 08:00AM  
Nov-05-20 04:05PM  
Oct-14-20 08:00AM  
Oct-08-20 08:32AM  
Sep-10-20 08:00AM  
Aug-28-20 08:00AM  
Aug-06-20 04:05PM  
Aug-05-20 08:00AM  
Jul-13-20 10:05AM  
Jul-06-20 08:00AM  
Jun-22-20 09:48AM  
Jun-18-20 08:00AM  
Jun-11-20 04:05PM  
May-18-20 11:34AM  
May-07-20 04:05PM  
Apr-22-20 04:05PM  
Mar-13-20 07:46AM  
Mar-11-20 04:05PM  
Dec-19-19 09:49AM  
Nov-24-19 01:56PM  
Nov-14-19 07:30AM  
Oct-30-19 04:05PM  
Oct-29-19 08:30AM  
Oct-03-19 04:01PM  
Oct-01-19 10:07AM  
Sep-30-19 01:00AM  
Sep-19-19 11:56AM  
Sep-03-19 08:00AM  
Aug-12-19 07:30AM  
Aug-06-19 08:00AM  
Jul-01-19 09:13AM  
Jun-27-19 08:00AM  
Jun-24-19 08:00AM  
Jun-20-19 11:13AM  
Jun-18-19 04:01PM  
Jun-13-19 08:00AM  
Jun-10-19 08:00AM  
Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. It is involved in developing Sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that has completed Phase II clinical trial for the treatment of multi-drug resistant Acinetobacter infections; Zoliflodacin, a novel orally administered molecule that has completed Phase II clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant Gram-negative infections. The company has collaboration agreements with Zai Lab (Shanghai) Co., Ltd. for developing SUL-DUR. Entasis Therapeutics Holdings Inc. was incorporated in 2018 and is based in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Innoviva, Inc.10% OwnerSep 01Buy2.684,672,89712,499,99918,672,897Sep 01 05:31 PM
Innoviva, Inc.10% OwnerJun 11Buy2.5012,677,49031,693,72514,000,000Jun 12 05:34 PM